Zhao 2015a.

Methods	Study design: Randomised clinical trial Study duration: July 2014 to July 2015 Duration of follow‐up: 3 years Setting: Hospital
Participants	Age (range ): 31‐64 years Male (n/total): 63/120
Interventions	TACE + RFA group (n = 60): TACE: Chemotherapeutic drugs: epirubicin 40 mg and oxaliplatin 100 mg RFA: The interval between TACE and RFA was 2 weeks. Cool‐tip ablation system. Ablation margin of 1 cm TACE group (n = 60): Chemotherapeutic drugs: epirubicin 40 mg and oxaliplatin 100 mg
Outcomes	Tumour necrosis rate, measured at 4 weeks after treatment by contrast‐enhanced CT 1‐, 2‐, and 3‐year disease progression rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.